# Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

> **NCT02541370** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chinese PLA General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Liver Cancer
- Pancreatic Cancer
- Brain Tumor
- Breast Cancer
- Ovarian Tumor
- Colorectal Cancer
- Acute Myeloid and Lymphoid Leukemias

## Interventions

- **BIOLOGICAL:** anti-CD133-CAR vector-transduced T cells

## Key facts

- **NCT ID:** NCT02541370
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02541370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02541370, "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02541370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*